Anat Cell Biol.  2015 Dec;48(4):235-243. 10.5115/acb.2015.48.4.235.

Protective effects of kaempferol against cardiac sinus node dysfunction via CaMKII deoxidization

• An M
• Kim M

• KMID: 2133262
• DOI: http://doi.org/10.5115/acb.2015.48.4.235

Abstract

Kaempferol exerts cardioprotective actions through incompletely understood mechanisms. This study investigated the molecular mechanisms underlying the cardioprotective effects of kaempferol in sinus node dysfunction (SND) heart. Here, we demonstrate that angiotensin II (Ang II) infusion causes SND through oxidized calmodulin kinase II (CaMKII). In contrast to this, kaempferol protects sinus node against Ang II-induced SND. Ang II evoked apoptosis with caspase-3 activation in sinus nodal cells. However, kaempferol lowered the CaMKII oxidization and the sinus nodal cell death. To block the CaMKII oxidization, gene of p47phox, a cytosolic subunit of NADPH oxidase, was deleted using Cas9 KO plasmid. In the absence of p47phox, sinus nodal cells were highly resistance to Ang II-induced apoptosis, suggesting that oxidized-CaMKII contributed to sinus nodal cell death. In Langendorff heart from Ang II infused mice, kaempferol preserved normal impulse formation at right atrium. These data suggested that kaempferol protects sinus node via inhibition of CaMKII oxidization and may be useful for preventing SND in high risk patients.

Keyword

Kaempferol; Sinus node dysfunction; CaMKII; Angiotensin II

MeSH Terms

Angiotensin II
Animals
Apoptosis
Calcium-Calmodulin-Dependent Protein Kinase Type 2*
Calcium-Calmodulin-Dependent Protein Kinases
Caspase 3
Cell Death
Cytosol
Heart
Heart Atria
Humans
Mice
NADPH Oxidase
Plasmids
Sick Sinus Syndrome*
Sinoatrial Node*
Angiotensin II
Calcium-Calmodulin-Dependent Protein Kinase Type 2
Calcium-Calmodulin-Dependent Protein Kinases
Caspase 3
NADPH Oxidase

Figure

• 

  Fig. 1 CaMKII oxidization and sinus node dysfunction in Ang II-infused mice. (A) Representative ECG recordings from Langendorff-perfused hearts isolated from mice infused with Ang II or saline for 3 weeks. (B) Ang II-infused mice have more sinus pauses than saline-infused mice. (C) Western blots shows ox-CaMKII and T-CaMKII from right atrial tissue obtained from infused with Ang II or saline for 3 weeks. Ang II, angiotensin II; CaMKII, calmodulin kinase II; ECG, electrocardiography; ox-CaMKII, oxidized-CaMKII; T-CaMKII, total CaMKII. Data are shown as the means±SEM of 3-6 mice per group. a)Significantly different (P<0.05) from saline infused control.

• 

  Fig. 2 Effect of Ang II on apoptosis with CaMKII oxidation. Cells were isolated from right atria and incubated with FBS for 1 day or 3 days. (A) Following the indicated days, protein was extracted to determine TBX3 (sinus node marker) and MLCA2 (cardiomyocyte marker) using Western blotting. Cells with dominant TBX3 expression were isolated and maintained using 20% FBS-DMEM. Subsequently, Ang II (20 µM) was added to the culture medium for 5 days. (B) Apoptotic cells were counted using TUNEL assay. Protein was extracted to measure caspase-3 activity (C) and determined ox-CaMKII and T-CaMKII using Western blotting (D). Ang II, angiotensin II; CaMKII, calmodulin kinase II; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; ox-CaMKII, oxidized-CaMKII; PBS, phosphate buffered saline; T-CaMKII, total CaMKII; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling. Data are shown as the means±SEM of 3-6 mice per group. a)Significantly different (P<0.05) from PBS treated control. b)Significantly different (P<0.05) from right atrial cells at 1st day. Scale bar=50 µm.

• 

  Fig. 3 Knockout of p47phox prevents sinus nodal cell death and CaMKII oxidization observed with Ang II. Cas9 KO plasmid transfection of p47phox in sinus nodal cell was performed using a Lipofectamine 3000. Plated cells were exposed to the Cas9 KO plasmid or empty vector control. After this, Ang II (20 µM) was added to the culture medium for 5 days. From these cells, ox-CaMKII levels (A), apoptotic cells (B), and caspase-3 activity (C) were evaluated. Ang II, angiotensin II; CaMKII, calmodulin kinase II; ox-CaMKII, oxidized-CaMKII; PBS, phosphate buffered saline; T-CaMKII, total CaMKII; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling. Data are shown as the means±SEM of 3-6 mice per group. a)Significantly different (P<0.05) from PBS treated control. b)Significantly different (P<0.05) from Ang II treated control. Scale bar=50 µm.

• 

  Fig. 4 Kaempferol reduces cell death by lowering CaMKII oxidization. Sinus nodal cells were incubated with Ang II (20 µM) in the absence or presence of a kaempferol (15 mM) for 5 days. Protein was extracted to determine ox-CaMKII using Western blotting (A) and measure caspase-3 activity (C). Apoptotic cells were counted using TUNEL assay (B). Ang II, angiotensin II; CaMKII, calmodulin kinase II; ox-CaMKII, oxidized-CaMKII; T-CaMKII, total CaMKII; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling. Data are shown as the means±SEM of 3-6 mice per group. a)Significantly different (P<0.05) from Ang II treated control. Scale bar=50 µm.

• 

  Fig. 5 Kaempferol improves the recovery of Ang II-induced sinus nodal dysfunction. (A) ECG recordings from Langendorff-perfused hearts isolated from mice infused with Ang II in the absence or presence of a kaempferol for 3 weeks. (B) Together with kaempferol, Ang II infused mice decreased sinus pauses than Ang II-infused alone. (C) Western blots demonstrates ox-CaMKII and T-CaMKII from right atrial tissue obtained from infused with Ang II, Ang II+kaempferol, or saline for 3 weeks. Ang II, angiotensin II; CaMKII, calmodulin kinase II; ECG, electrocardiography; ox-CaMKII, oxidized-CaMKII; T-CaMKII, total CaMKII. Data are shown as the means±SEM of 3-6 mice per group. a)Significantly different (P<0.05) from Saline treated control. b)Significantly different (P<0.05) from Ang II treated control.

• 

  Fig. 6 Schematic mechanism for kaempferol regulation of sinus node protection. After activation of sinus nodal NADPH oxidase with Ang II, increased amounts of ROS promote CaMKII oxidization which then mediates apoptosis through caspase-3. Following the apoptosis, reducing the sinus node volume causes sinus node dysfunction. Inhibition of NADPH oxidase by kaempferol attenuates CaMKII oxidization and apoptosis of sinus nodal cells, leading to a reduction of sinus node dysfunction. Ang II, angiotensin II; CaMKII, calmodulin kinase II; ox-CaMKII, oxidized-CaMKII; ROS, reactive oxygen species.

Reference

1. Liu J, Xin L, Benson VL, Allen DG, Ju YK. Store-operated calcium entry and the localization of STIM1 and Orai1 proteins in isolated mouse sinoatrial node cells. Front Physiol. 2015; 6:69.

2. Milanesi R, Bucchi A, Baruscotti M. The genetic basis for inherited forms of sinoatrial dysfunction and atrioventricular node dysfunction. J Interv Card Electrophysiol. 2015; 43:121–134.

3. Swulius MT, Waxham MN. Ca(2+)/calmodulin-dependent protein kinases. Cell Mol Life Sci. 2008; 65:2637–2657.

4. Yang LZ, Kockskämper J, Khan S, Suarez J, Walther S, Doleschal B, Unterer G, Khafaga M, Mächler H, Heinzel FR, Dillmann WH, Pieske B, Spiess J. cAMP- and Ca(2)(+) /calmodulin-dependent protein kinases mediate inotropic, lusitropic and arrhythmogenic effects of urocortin 2 in mouse ventricular myocytes. Br J Pharmacol. 2011; 162:544–556.

5. Wang Y, Cui H, Wang W, Zhao B, Lai J. The region-specific activation of Ca2+/calmodulin dependent protein kinase II and extracellular signal-regulated kinases in hippocampus following chronic alcohol exposure. Brain Res Bull. 2012; 89:191–196.

6. Huynh QK, Pagratis N. Kinetic mechanisms of Ca++/calmodulin dependent protein kinases. Arch Biochem Biophys. 2011; 506:130–136.

7. Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV, Bartlett RK, Lowe JS, O'Donnell SE, Aykin-Burns N, Zimmerman MC, Zimmerman K, Ham AJ, Weiss RM, Spitz DR, Shea MA, Colbran RJ, Mohler PJ, Anderson ME. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell. 2008; 133:462–474.

8. Santalla M, Valverde CA, Harnichar E, Lacunza E, Aguilar-Fuentes J, Mattiazzi A, Ferrero P. Aging and CaMKII alter intracellular Ca2+ transients and heart rhythm in Drosophila melanogaster. PLoS One. 2014; 9:e101871.

9. Di Carlo MN, Said M, Ling H, Valverde CA, De Giusti VC, Sommese L, Palomeque J, Aiello EA, Skapura DG, Rinaldi G, Respress JL, Brown JH, Wehrens XH, Salas MA, Mattiazzi A. CaMKII-dependent phosphorylation of cardiac ryanodine receptors regulates cell death in cardiac ischemia/reperfusion injury. J Mol Cell Cardiol. 2014; 74:274–283.

10. Szobi A, Rajtik T, Carnicka S, Ravingerova T, Adameova A. Mitigation of postischemic cardiac contractile dysfunction by CaMKII inhibition: effects on programmed necrotic and apoptotic cell death. Mol Cell Biochem. 2014; 388:269–276.

11. Zhao HR, Jiang T, Tian YY, Gao Q, Li Z, Pan Y, Wu L, Lu J, Zhang YD. Angiotensin II triggers apoptosis via enhancement of NADPH oxidase-dependent oxidative stress in a dopaminergic neuronal cell line. Neurochem Res. 2015; 40:854–863.

12. Carney EF. Hypertension: vascular type 1A angiotensin II receptors regulate renal blood flow and natriuresis. Nat Rev Nephrol. 2015; 11:318.

13. Rincon J, Correia D, Arcaya JL, Finol E, Fernández A, Pérez M, Yaguas K, Talavera E, Chávez M, Summer R, Romero F. Role of angiotensin II type 1 receptor on renal NAD(P)H oxidase, oxidative stress and inflammation in nitric oxide inhibition induced-hypertension. Life Sci. 2015; 124:81–90.

14. Swaminathan PD, Purohit A, Soni S, Voigt N, Singh MV, Glukhov AV, Gao Z, He BJ, Luczak ED, Joiner ML, Kutschke W, Yang J, Donahue JK, Weiss RM, Grumbach IM, Ogawa M, Chen PS, Efimov I, Dobrev D, Mohler PJ, Hund TJ, Anderson ME. Oxidized CaMKII causes cardiac sinus node dysfunction in mice. J Clin Invest. 2011; 121:3277–3288.

15. Zhang R, Khoo MS, Wu Y, Yang Y, Grueter CE, Ni G, Price EE Jr, Thiel W, Guatimosim S, Song LS, Madu EC, Shah AN, Vishnivetskaya TA, Atkinson JB, Gurevich VV, Salama G, Lederer WJ, Colbran RJ, Anderson ME. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med. 2005; 11:409–417.

16. Luo M, Guan X, Luczak ED, Lang D, Kutschke W, Gao Z, Yang J, Glynn P, Sossalla S, Swaminathan PD, Weiss RM, Yang B, Rokita AG, Maier LS, Efimov IR, Hund TJ, Anderson ME. Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J Clin Invest. 2013; 123:1262–1274.

17. McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. Am J Clin Nutr. 2012; 95:454–464.

18. Esmaillzadeh A, Azadbakht L. Dietary flavonoid intake and cardiovascular mortality. Br J Nutr. 2008; 100:695–697.

19. Chong MF, George TW, Alimbetov D, Jin Y, Weech M, Macready AL, Spencer JP, Kennedy OB, Minihane AM, Gordon MH, Lovegrove JA. Impact of the quantity and flavonoid content of fruits and vegetables on markers of intake in adults with an increased risk of cardiovascular disease: the FLAVURS trial. Eur J Nutr. 2013; 52:361–378.

20. Barbosa E, Calzada F, Campos R. In vivo antigiardial activity of three flavonoids isolated of some medicinal plants used in Mexican traditional medicine for the treatment of diarrhea. J Ethnopharmacol. 2007; 109:552–554.

21. Xiao HB, Jun F, Lu XY, Chen XJ, Chao T, Sun ZL. Protective effects of kaempferol against endothelial damage by an improvement in nitric oxide production and a decrease in asymmetric dimethylarginine level. Eur J Pharmacol. 2009; 616:213–222.

22. Wang SB, Jang JY, Chae YH, Min JH, Baek JY, Kim M, Park Y, Hwang GS, Ryu JS, Chang TS. Kaempferol suppresses collagen-induced platelet activation by inhibiting NADPH oxidase and protecting SHP-2 from oxidative inactivation. Free Radic Biol Med. 2015; 83:41–53.

23. James TN, St Martin E, Willis PW 3rd, Lohr TO. Apoptosis as a possible cause of gradual development of complete heart block and fatal arrhythmias associated with absence of the AV node, sinus node, and internodal pathways. Circulation. 1996; 93:1424–1438.

24. Hoogaars WM, Engel A, Brons JF, Verkerk AO, de Lange FJ, Wong LY, Bakker ML, Clout DE, Wakker V, Barnett P, Ravesloot JH, Moorman AF, Verheijck EE, Christoffels VM. Tbx3 controls the sinoatrial node gene program and imposes pacemaker function on the atria. Genes Dev. 2007; 21:1098–1112.

25. Myers FB, Silver JS, Zhuge Y, Beygui RE, Zarins CK, Lee LP, Abilez OJ. Robust pluripotent stem cell expansion and cardiomyocyte differentiation via geometric patterning. Integr Biol (Camb). 2013; 5:1495–1506.

26. Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, Raval KK, Zhang J, Kamp TJ, Palecek SP. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A. 2012; 109:E1848–E1857.

27. Jordan JL, Yamaguchi I, Mandel WJ. Studies on the mechanism of sinus node dysfunction in the sick sinus syndrome. Circulation. 1978; 57:217–223.

28. Nitardy A, Langreck H, Dietz R, Stockburger M. Reduction of right ventricular pacing in patients with sinus node dysfunction through programming a long atrioventricular delay along with the DDIR mode. Clin Res Cardiol. 2009; 98:25–32.

29. Le Scouarnec S, Bhasin N, Vieyres C, Hund TJ, Cunha SR, Koval O, Marionneau C, Chen B, Wu Y, Demolombe S, Song LS, Le Marec H, Probst V, Schott JJ, Anderson ME, Mohler PJ. Dysfunction in ankyrin-B-dependent ion channel and transporter targeting causes human sinus node disease. Proc Natl Acad Sci U S A. 2008; 105:15617–15622.

30. Nof E, Antzelevitch C, Glikson M. The contribution of HCN4 to normal sinus node function in humans and animal models. Pacing Clin Electrophysiol. 2010; 33:100–106.

31. Lee JM, Kalman JM. Sinus node dysfunction and atrial fibrillation: two sides of the same coin? Europace. 2013; 15:161–162.

32. Kim DS, Ha KC, Kwon DY, Kim MS, Kim HR, Chae SW, Chae HJ. Kaempferol protects ischemia/reperfusion-induced cardiac damage through the regulation of endoplasmic reticulum stress. Immunopharmacol Immunotoxicol. 2008; 30:257–270.